JP2022523045A5 - - Google Patents

Info

Publication number
JP2022523045A5
JP2022523045A5 JP2021543165A JP2021543165A JP2022523045A5 JP 2022523045 A5 JP2022523045 A5 JP 2022523045A5 JP 2021543165 A JP2021543165 A JP 2021543165A JP 2021543165 A JP2021543165 A JP 2021543165A JP 2022523045 A5 JP2022523045 A5 JP 2022523045A5
Authority
JP
Japan
Application number
JP2021543165A
Other languages
Japanese (ja)
Other versions
JP2022523045A (ja
JPWO2020159822A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/014953 external-priority patent/WO2020159822A1/en
Publication of JP2022523045A publication Critical patent/JP2022523045A/ja
Publication of JP2022523045A5 publication Critical patent/JP2022523045A5/ja
Publication of JPWO2020159822A5 publication Critical patent/JPWO2020159822A5/ja
Pending legal-status Critical Current

Links

JP2021543165A 2019-01-28 2020-01-24 ツカチニブを用いて乳がんを処置する方法 Pending JP2022523045A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962797854P 2019-01-28 2019-01-28
US62/797,854 2019-01-28
PCT/US2020/014953 WO2020159822A1 (en) 2019-01-28 2020-01-24 Methods of treating breast cancer with tucatinib

Publications (3)

Publication Number Publication Date
JP2022523045A JP2022523045A (ja) 2022-04-21
JP2022523045A5 true JP2022523045A5 (https=) 2023-02-02
JPWO2020159822A5 JPWO2020159822A5 (https=) 2023-02-02

Family

ID=69740562

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543165A Pending JP2022523045A (ja) 2019-01-28 2020-01-24 ツカチニブを用いて乳がんを処置する方法

Country Status (13)

Country Link
US (1) US20220193076A1 (https=)
EP (1) EP3917533A1 (https=)
JP (1) JP2022523045A (https=)
KR (1) KR20210119498A (https=)
CN (1) CN113613656A (https=)
AR (1) AR119681A1 (https=)
AU (1) AU2020215551A1 (https=)
CA (1) CA3126279A1 (https=)
IL (1) IL284850A (https=)
MX (1) MX2021008834A (https=)
SG (1) SG11202107488PA (https=)
TW (1) TW202042820A (https=)
WO (1) WO2020159822A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3060407A1 (en) 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
US20230372342A1 (en) * 2020-09-28 2023-11-23 Seagen Inc. Methods of treating solid tumors driven by her2 alterations with tucatinib in combination with an anti-her2 antibody
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CN117243959B (zh) * 2022-10-13 2026-03-06 山东大学 治疗骨质疏松的方法和药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
CA3060407A1 (en) * 2017-04-28 2018-11-01 Seattle Genetics, Inc. Treatment of her2 positive cancers

Similar Documents

Publication Publication Date Title
BR112021014123A2 (https=)
JP2022523045A5 (https=)
JP2023543261A5 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)
BR102021016176A2 (https=)
BR102021015566A2 (https=)
BR102021015450A8 (https=)
BR102021015220A2 (https=)
BR102021015247A2 (https=)
BR102021014056A2 (https=)
BR102021014044A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)
BR102021012230A2 (https=)
BR102021012003A2 (https=)
BR102021012107A2 (https=)